

AD \_\_\_\_\_

Award Number: DAMD17-00-1-0038

TITLE: TGFB1 Regulation of Matrix Metalloproteinase-9 in Human Prostate Cancer Metastasis

PRINCIPAL INVESTIGATOR: Inder Sehgal, Ph.D.

CONTRACTING ORGANIZATION: North Dakota State University  
Fargo, North Dakota 58105-5756

REPORT DATE: June 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020118 120

**REPORT DOCUMENTATION PAGE***Form Approved*  
*OMB No. 074-0188*

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

**1. AGENCY USE ONLY (Leave blank)****2. REPORT DATE**

June 2001

**3. REPORT TYPE AND DATES COVERED**

Annual (15 May 00 - 14 May 01)

**4. TITLE AND SUBTITLE**

TGFB1 Regulation of Matrix Metalloproteinase-9 in Human Prostate Cancer Metastasis

**5. FUNDING NUMBER**

DAMD17-00-1-0038

**6. AUTHOR(S)**

Inder Sehgal, Ph.D.

**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**

North Dakota State University  
 Fargo, North Dakota 58105-5756  
 Email - [inder\\_sehgal@ndsu.nodak.edu](mailto:inder_sehgal@ndsu.nodak.edu)

**8. PERFORMING ORGANIZATION REPORT NUMBER****9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)**

U.S. Army Medical Research and Materiel Command  
 Fort Detrick, Maryland 21702-5012

**10. SPONSORING / MONITORING AGENCY REPORT NUMBER****11. SUPPLEMENTARY NOTES****12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

**12b. DISTRIBUTION CODE****13. ABSTRACT (Maximum 200 Words)**

Matrix Metalloproteinases (MMPs) facilitate invasion, growth factor activation, and angiogenesis during the metastasis of prostate cancer and they have become a popular target for anti-metastasis agents. Existing anti-MMP drugs are synthetically designed pharmacologic antagonists with a relatively broad spectrum of action and clinical toxicities which have proven unacceptable. This New Investigator research pursues an alternative approach to these toxic chemicals. We focus on one MMP--MMP-9 because it is clinically linked with prostate cancer metastasis and can be induced from very low to high levels in prostate cancer cells by TGFβ1, which is itself clinically and experimentally associated with prostate cancer metastasis. We are attacking the proteinase at the level of transcription. Transcriptional upregulation of MMP-9 by TGFβ involves an enhancement of the stability of the MMP-9 mRNA molecules. Understanding how this increased mRNA stability occurs is our project's goal. We are attempting to identify new targets on the MMP-9 transcript protected by the induction or repression of RNA-binding proteins induced by TGFβ1. We are also attempting to isolate and attempt to identify these TGFβ-regulated proteins.

**14. SUBJECT TERMS**

Prostate Cancer

**15. NUMBER OF PAGES**

6

**16. PRICE CODE****17. SECURITY CLASSIFICATION OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION OF ABSTRACT**

Unclassified

**20. LIMITATION OF ABSTRACT**

Unlimited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
 Prescribed by ANSI Std. Z39-18  
 298-102

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	5
Conclusions.....	5
References.....	6
Appendices.....	

## Introduction

The purpose of this New Investigator grant is to target matrix metalloproteinases that abet prostate cancer metastasis. Our approach is to attack the proteinase MMP-9 at the level of transcription by understanding that in prostate cancer cells, this important enzyme is in part upregulated by the cytokine TGF $\beta$ 1. This upregulation involves enhancing the stability of the MMP-9 mRNA molecules. We proposed to identify targets on the MMP-9 transcript which may be protected by the induction or repression of RNA-binding proteins induced by TGF $\beta$ 1. We further proposed to isolate and attempt to identify these TGF $\beta$ -regulated proteins. Our aims involve initially biochemical assays (eg gel-shift) and then cell-based (transfections) experiments.

## Body

In our Statement of Work, we outlined 3 Specific aims encompassing 5 tasks. Portions of the first two aims were to begin in year one. Specific Aim 1 was to map the MMP-9 transcript's 3'untranslated region (UTR), for broad and then narrow regions critical to maintenance of transcript stability. Our first task was to begin by constructing several new plasmids with deletions of relatively large regions within the MMP-9 3'UTR. We have thus far designed and built 2 constructs: one with the entire 500 bp 3'UTR deleted leaving a 2000 bp coding region (2.0 kb fragment MMP-9); and one with only the 3'UTR left (0.5 kb fragment MMP-9). We have also made (or are in the process of making) constructs with the coding region plus the first 100 bp of the 3'UTR, the first 200 bp of the UTR, the first 300 bp of the UTR and the first 400 (out of approximately 500 bp) of the MMP-9 UTR. In this way, we will have constructs with the MMP-9 coding region covering 100 nucleotide stretches of the entire 3'UTR in a Bluescript vector to use for in vitro transcription.

In our Specific Aim 2, we proposed to analyze broad then smaller transcripts from constructs made in Aim 1 for TGF $\beta$ 1-regulated protein-binding. We have acquired, grown and collected cytosolic and nuclear lysates (Marzluff et al, 1997) from 4 prostate cancer cell lines (DU145, PC-3, Tsu-Pr1, ND-1) with or without TGF $\beta$ 1-stimulation. These lysates will be incubated with 3'UTR transcripts via RNA gel-shift to identify potential TGF $\beta$ 1-regulated protein-bound regions (Bagga et al., 1999; Bagga and Wilusz, 1995).

Problems in Year 1: In the initial proposal, I had enlisted 2 graduate students, Ms. Li Qin and Ms. Sarah Holmes for these studies. Ms. Qin left my laboratory to pursue a graduate degree in Statistics and Ms. Holmes left to enter the Pharmacy Doctoral program. I have recruited one graduate student into the group (Ms. Andrea Grief), one undergraduate (Mr. Jeffery Lachowitz) and one Pharm D student, Mr. William Fischer) to work on this project. In addition, I am in the process of recruiting a technician (to be paid out of the NIH COBRE grant described below). There was a loss of continuity and productivity after the departures of Ms. Qin and Holmes because I had to retrain (and am still training) my 3 new group members. In addition, because of the COBRE award to study MMPs in cancer, my laboratory will undergo extensive remodeling—a new tissue culture facility will be constructed this year. This facility will include the addition of two new tissue culture hoods, 2 new microscopes, incubators, and work bench areas. In addition, I will have a newly constructed dark room attached to the laboratory for processing of gel shift films. This remodeling and the asbestos removal which

must accompany it, will necessitate that the laboratory and cell culture be temporarily moved and closed part of this next year. I anticipate that the inefficiency associated with this moving will necessitate stretching this DOD award out over 4 years vs. 3.

#### Key Research Accomplishments

- Construction of plasmids with 100 bp deletions covering the MMP-9 3'UTR.
- Collection of cytosolic and nuclear extract from prostate cell lines

#### Reportable Outcomes

In 2000, I applied for an NIH RFA program grant along with a group of 5 other investigators. This grant award, called a C-O-B-R-E (Center of Biomedical Research Excellence) is set aside for EPSCoR state universities to fund infrastructure and research proposals to enhance competitiveness within these states. This award was funded in February of 2001 and as a result, I will run a cell culture facility to test newly developed MMP inhibitors. Much of the background for my aspect of this grant came about as a result of this DOD award. The building renovations described above which will be of tremendous benefit to the aims of this DOD award, will be paid for from this COBRE money.

#### Conclusions

Our preparations thus far will allow us to run several gel-shifts in year 2. The implications are that these experiments may demonstrate regions within the UTR necessary for TGF $\beta$ 1 regulation, if this regulation is through an enhanced protein binding or reduced binding, and if the proteins are cytosolic or nuclear. Constructs which appear to have altered protein binding after TGF $\beta$  treatment will be subcloned into mammalian expression vectors. We will transfect the prostate cancer cells with these vectors to determine if the TGF $\beta$ -induced increase in MMP-9 half-life at the levels of the RNA and protein products are altered with the 3'UTR deletions.

"So What Section"—Our experimental process is still in the foundation building stage; however with our constructs and cell lysates, we have the reagents to provide answers about how this critical MMP is regulated by a critical growth factors during prostate cancer metastasis.

## References

Bagga P., Ford, L, Chen, F and Wilusz, J. the G-rich auxiliary downstream element has distinct sequence and position requirements and mediates efficient 3' end pre-mRNA processing through a trans-acting factor. *Nucleic Acids Res.* 23:1625-31, 1995.

Bagga, p and Wilusz, J. Northwestern screening of expression libraries. *In: Methods in molecular biology*, vol. 118: RNA-protein interaction protocols. ed. Susan Haynes Humana Press Inc. 1999.

Marzluff, W.F., Whitfield, M.L., Dominski, Z., and Wang Z-F. Identification of the protein that interacts with the 3' end of histone mRNA. *In: mRNA Formation and Function*, ed. Joel D. Richter. Academic Press 1997.

Appendices None